On June 25, the reporter learned from the National Medical Products Administration (NMPA) that Cinda's two innovative drugs, Daboshu and Dayotong, were used in combination and formally approved for the first-line treatment of advanced liver cancer
Liver cancer is a common malignant tumor of the digestive system in the world.
Daboshu is a PD-1 inhibitor that has attracted much attention in the field of tumor immunotherapy, which "kills" cancer cells by activating immune cells
Based on this, the results of a randomized, controlled, open multi-center phase III clinical study led by Fan Jia, an academician of the Chinese Academy of Sciences, to use Daboshu and Dayou in the first-line treatment of advanced liver cancer showed that compared with traditional standard targeted drugs Treatment, the median overall survival (OS) of the combined treatment regimen has not yet reached (traditional standard targeted drug therapy 10.
Related paper information: https://doi.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
